Johnson & Johnson on Tuesday reported lower-than- expected quarterly revenue after sales of its COVID-19 vaccine missed Wall Street estimates following a string of production setbacks. The New Brunswick, New Jersey-based company maintained its 2021 sales goal of $2.5 billion from the vaccine, and said it recorded $766 million in sales of the shot in the first nine months of 2021—which indicates that sales will have to more than triple in the fourth quarter to meet its forecast. “We’re still very much committed to the $2.5 billion of revenue and the supply that is correlated to that,” Chief Financial Officer Joseph Wolk told investors on a conference call. The drugmaker earlier this year experienced quality problems at a Baltimore manufacturing facility that produces the single-dose vaccine, resulting in wastage of millions of doses. The J&J shot, once touted an as important tool for vaccinating hard-to-reach areas, is behind its schedule …